SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

OFFICIAL TRUMP (TRUMP) is a cryptocurrency and operates on the Solana platform. OFFICIAL TRUMP has a current supply of 999,998,811.032761 with 281,866,747.320393 in circulation. The last known price of OFFICIAL TRUMP is 1.57555883 USD and is down -1.93 over the last 24 hours. It is currently trading on 744 active market(s) with $126,884,732.61 traded over the last 24 hours. More information can be found at https://gettrumpmemes.com/.

Trump For President

The TRUMP meme coin is drawing attention amid discussion of its steep decline from launch highs and allegations that Trump-linked insiders profited while retail holders lost money. Many traders call it a scam and expect further downside, while some remain bullish on accumulation or a possible short squeeze.

Occidental Petroleum Corp. engages in the exploration and production of oil and natural gas. It operates through the following segments: Oil and Gas, Chemical, and Midstream and Marketing. The Oil and Gas segment explores for, develops and produces oil and condensate, natural gas liquids, and natural gas. The Chemical segment manufactures and markets basic chemicals and vinyls. The Midstream and Marketing segment purchases, markets, gathers, processes, transports and stores oil, condensate, natural gas liquids, natural gas, carbon dioxide, and power. The company was founded in 1920 and is headquartered in Houston, TX.

Occidental Petroleum Corp.

OXYs breakout to a six-month high amid strength in oil stocks is drawing attention, with bullish call-option activity adding to the momentum. Traders are watching for follow-through, while others question why the shares have not tracked crude prices more closely and point to resistance ahead.

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Stockholm, Sweden.

Spotify Technology S.A.

Spotify shares are rallying after its latest quarterly report, as subscriber growth, improving gross margin and a stronger profit outlook outweighed modest revenue and EPS misses. Traders are debating the disconnect between the headline misses and the positive market reaction, with many pointing to forward guidance as the key driver.

Blue Owl Capital, Inc. operates as an alternative asset management firm. It provides investors access to asset management capital solutions through its Direct Lending and GP Capital Solutions products. The company offers a platform of capital solutions to both middle market companies and large alternative asset managers. The company was founded by Doug Irving Ostrover, Michael Rees and Craig W.Packer in 2009 and is headquartered in New York, NY.

Blue Owl Capital Inc - Ordinary Shares - Class A

Blue Owls Q3 results and upbeat earnings-call outlook are driving attention, with traders highlighting fee and AUM growth, dividend coverage, and unearned-fee backlog as reasons for optimism. Some remain cautious about private-credit redemptions and whether fee growth is durable, while bullish traders see the results as a counterpoint to lingering sector concerns.

Blackstone, Inc. engages in the provision of investment and fund management services. It operates through the following segments: Real Estate, Private Equity, Credit and Insurance, and Hedge Fund Solutions. The Real Estate segment includes management of opportunistic real estate funds, Core+ real estate funds, high-yield real estate debt funds, and liquid real estate debt funds. The Private Equity segment consists of management of flagship corporate private equity funds, sector and geographically focused corporate private equity funds, core private equity funds, an opportunistic investment platform, a secondary fund of funds business, infrastructure-focused funds, a life sciences investment platform, a growth equity investment platform, a multi-asset investment program for eligible high net worth investors and a capital markets services business. The Credit and Insurance segment refers to Blackstone Credit, which is organized into two overarching strategies: private credit which includes mezzanine direct lending funds, private placement strategies, stressed and distressed strategies and energy strategies, and liquid credit which consists of CLOs, closed-ended funds, open ended funds and separately managed accounts. In addition, the segment includes an insurer-focused platform, an asset-based finance platform, and publicly traded master limited partnership investment platform. The Hedge Fund Solutions segment focuses on Blackstone Alternative Asset Management, which manages a broad range of commingled and customized hedge fund of fund solutions. It also includes a GP Stakes business and investment platforms that invest directly, as well as investment platforms that seed new hedge fund businesses and create alternative solutions through daily liquidity products. The company was founded by Stephen Allen Schwarzman in 1985 and is headquartered in New York, NY.

Blackstone Inc

Blackstones reported expectation that Anthropic could receive a speculative-grade credit rating, reversing its earlier outlook, has drawn attention amid scrutiny of AI financing risk. Traders debate whether the report intensified selling, while call-heavy options activity is viewed by some as positioning rather than a clear bullish bet.

Chevron Corp. engages in the provision of oil and gas energy solutions. It provides crude oil and natural gas, manufactures transportation fuels, lubricants, petrochemicals, and additives, and develops technologies that enhance business and the industry. It operates through the Upstream and Downstream segments. The Upstream segment consists of the exploration, development, and production of crude oil and natural gas, the liquefaction, transportation, and regasification associated with liquefied natural gas, the transporting of crude oil by major international oil export pipelines, the processing, transporting, storage, and marketing of natural gas, and a gas-to-liquids plant. The Downstream segment consists of the refining of crude oil into petroleum products, the marketing of crude oil and refined products, the transporting of crude oil and refined products by pipeline, marine vessel, motor equipment, and rail car, and the manufacturing and marketing of commodity petrochemicals and plastics for industrial uses and fuel & lubricant additives. The company was founded on September 10, 1879 and is headquartered in Houston, TX.

Chevron Corp.

Chevrons Q3 earnings beat, driven in part by strong refining margins and record U.S. refinery throughput, is the main catalyst. Traders are reacting bullishly to the results and call-heavy options activity, while some question whether the refining boost will last.

Pyth Network (PYTH) is a cryptocurrency launched in 2021and operates on the Solana platform. Pyth Network has a current supply of 9,999,981,857.422035 with 7,874,958,862.767691 in circulation. The last known price of Pyth Network is 0.06608465 USD and is up 1.61 over the last 24 hours. It is currently trading on 450 active market(s) with $21,484,088.50 traded over the last 24 hours. More information can be found at https://pyth.network/.

Pyth Network

Pyths Nasdaq data-distribution and broader real-world-asset push are fueling bullish discussion, alongside the DAOs policy directing product revenue toward PYTH reserve accumulation. Traders see these developments as strengthening the tokens demand story, while others point to weak price action and potential token-unlock selling pressure.

VXX tracks an index with exposure to futures contracts on the CBOE Volatility Index with average one-month maturity. Exposure resets daily.

Barclays Bank PLC - iPathÂ® Series B S&P 500Â® VIX Short-Term FuturesTM ETN

iPath S&P 500 VIX Short-Term Futures ETN

A rebound in volatility has put VXX in focus as traders weigh hedging for a possible market pullback amid broader uncertainty. Some see the move as the start of a sustained volatility breakout, while others expect a short-lived pop and point to VXXs futures-related decay as a reason to fade rallies.

Churchill Capital Corp. XI is a blank check company. It was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded by Michael Stuart Klein on June 4, 2025 and is headquartered in New York, NY.

Churchill Capital Corp XI - Ordinary Shares - Class A

CCXI is drawing attention as the SPAC vehicle for Agility Robotics and its humanoid-robotics business, with traders debating the companys commercial potential and industry momentum against concerns about losses, valuation, dilution, and the loss of SPAC redemption support. The community is split between bullish bets on robotics and cautious reactions to the sharp decline and downside-leaning options activity.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Regenerons strong third-quarter earnings beat is driving a sharp rally and a new 52-week high, with traders highlighting growth across Dupixent, Eylea HD and Libtayo. The reaction is broadly bullish, though some note that declining legacy Eylea sales and potential profit-taking could temper the momentum.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Gilead Sciences (GILD) Q3 Earnings and Revenues Top Estimates

Gilead (GILD) delivered earnings and revenue surprises of +17.51% and +6.21%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Harmony Biosciences Holdings, Inc. (HRMY) Reports Next Week: Wall Street Expects Earnings Growth

Harmony Biosciences (HRMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Tarsus Pharmaceuticals, Inc. (TARS) Q3 Earnings Expected to Decline

Tarsus Pharmaceuticals (TARS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates

Tarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of -104.76% and +5.01%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Agenus (AGEN) Earnings Expected to Grow: Should You Buy?

Agenus (AGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Tarsus Pharmaceuticals, Inc. (TARS) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

All You Need to Know About Tarsus Pharmaceuticals (TARS) Rating Upgrade to Buy

Tarsus Pharmaceuticals (TARS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Tarsus Pharmaceuticals (TARS) Moves 7.5% Higher: Will This Strength Last?

Tarsus Pharmaceuticals (TARS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

TARS Stock Drops After Culper Research Accuses Tarsus Of Illegal Medicare Copay Scheme

Equity

Culper’s central allegation is that Tarsus has driven XDEMVY uptake among Medicare patients by funding copay assistance. 


Tarsus Pharmaceuticals Stock Drops as Short Seller Alleges Illegal Copay Scheme

Tarsus Pharmaceuticals Inc (NASDAQ:TARS) shares are falling Wednesday. Short-seller Culper Research published a report Wednesday alleging the company's sole commercial product relies on an illegal Medicare copay scheme. Here's what you should know.read more...

Tarsus Pharmaceuticals, Inc. is a commercial stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. It is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA.

Tarsus Pharmaceuticals Inc

Bearish Sentiment

<ul class="summary-bullets"><li>Culper also alleged that Tarsus inflated its total addressable market estimate. &nbsp;</li><li>The firm further asserts that Tarsus will miss 2026 guidance.</li><li>Retail traders dismissed Culper’s claims, highlighting its past record of shorting Praxis Precision and Axsome Therapeutics.</li></ul>Tarsus Pharmaceuticals (TARS) shares fell about 5% on Wednesday after short seller Culper Research revealed its short position in the stock and published a detailed report accusing the company of using questionable practices to drive sales of its sole product, XDEMVY.The stock is now on track to clock its worst day since April.<h2 class="st-heading-2">Alleged Medicare Copay Scheme</h2>Culper’s central allegation is that Tarsus has driven XDEMVY uptake among Medicare patients by funding copay assistance through the HealthWell Foundation’s blepharitis fund, launched in September 2023— shortly after XDEMVY’s approval. The report claims Tarsus donations, $5.7 million in 2023 and $31.2 million in 2024, closely match the fund’s total receipts, suggesting Tarsus is effectively the sole major donor.This structure, Culper argues, violates the Anti-Kickback Statute (AKS). Similar copay schemes have led to large DOJ settlements.The report notes that Tarsus previously disclosed “patient assistance donations” in its earnings as selling, general, and administrative costs before reclassifying the spending. One specialty pharmacy reportedly steers Medicare patients to the fund, and Culper claims 50% of Medicare XDEMVY patients use it.XDEMVY is the first and only FDA-approved prescription eye drop designed to directly target and kill Demodex mites, the root cause of Demodex blepharitis. It is Tarsus’s sole commercial product.<h2 class="st-heading-2">Inflated Total Addressable Market</h2>Tarsus has touted a 25 million U.S. patient opportunity for Demodex blepharitis, implying peak XDEMVY sales above $2 billion. Culper calls this “wildly inflated.” A survey of 30 current prescribers found only 18% of their patients had the condition, implying a true total addressable market closer to 5 million.The report contends that Tarsus equates any collarettes, common even in healthy people, with clinical disease and downplays that XDEMVY is a one-time six-week course with limited retreatment. Tarsus has already treated roughly 600,000 of the 1.5 million ever-diagnosed patients. Culper estimates peak annual revenues below $800 million.Financial Miss LikelyCulper asserts Tarsus will miss 2026 guidance. “Patient assistance” and other SG&amp;A costs are rising sharply and are under-modeled by analysts. Consensus forecasts remain too optimistic, the report says, pointing to ballooning expenses hidden in legal and IT lines.<h2 class="st-heading-2">How Did TARS Retail Traders React?</h2>On Stocktwits, retail sentiment around TARS stock fell from bullish to neutral territory over the past 24 hours, while message volume stayed at high levels.A Stocktwits user refuted Culper’s claims of a small total addressable market for XDEMVY.<stembedurl>https://www.stocktwits.com/Biotechace/message/658074096</stembedurl>Another user highlighted Culper’s<a href="https://stocktwits.com/news-articles/markets/equity/praxis-precision-medicines-stock-drops-after-culper-research-reveals-short-position/cLPAFl6REaV"> track record</a>, previously shorting Praxis Precision and Axsome Therapeutics, both of which are trading at significant premiums since.<stembedurl>https://www.stocktwits.com/CH_Expat/message/658071922</stembedurl><a href="https://stocktwits.com/symbol/TARS">TARS stock</a> has fallen 26% year-to-date.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/rivian-ceo-flags-memory-chip-shortage-risk-for-r2-production-retail-eyes-q2-delivery-numbers/cZm3NOgR71X">Rivian CEO Flags Memory Chip Shortage Risk For R2 Production – Retail Eyes Q2 Delivery Numbers</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Tarsus Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Culper’s central allegation is that Tarsus has driven XDEMVY uptake among Medicare patients by funding copay assistance. 

Axsome Therapeutics Inc

iShares Russell 2000 ETF

Praxis Precision Medicines Inc

Vanguard Total Stock Market ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Stocktwits

Stocktwits Polls

$TARS this is heading back up, good time to add...# scripts for Xdemvy just keep rising and more providers on board daily.  Last continuing education meeting, 3 of 4 lecturers talked about Lotilaner (Xdemvy) as 1st line treatment for the extremely common finding of demodex blepharitis.  I have retreated many patients with demodex blepharitis with Xdemvy so it's not a one and done ... momentum will keep building.

$TARS this company is so under the radar and so under rated. Will do 700 mil in revenue in its third year of launch. Four late stage blockbusters in pipeline all with unmet medical needs.

$TARS if u can hold tarsus for 5 years and if all the pipeline assets are successful, u will be looking at 5 block busters with unmet medical needs. Market cap could potentially 10x. This is no joke. Just saying…

$TARS added another 500 today. Sell the rips and buy the dips is the only way to play this one.￼

Feed

News

Sentiment

Earnings

Fundamentals

Info

TARS Tarsus Pharmaceuticals Inc

Fundamentals

Latest TARS News